Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Mol Pharmacol. 2012 Mar;81(3):420-30. doi: 10.1124/mol.111.075630. Epub 2011 Dec 9.
Platelet activation is important in the regulation of hemostasis and thrombosis. Uncontrolled activation of platelets may lead to arterial thrombosis, which is a major cause of myocardial infarction and stroke. After activation, metabolism of arachidonic acid (AA) by 12-lipoxygenase (12-LOX) may play a significant role in regulating the degree and stability of platelet activation because inhibition of 12-LOX significantly attenuates platelet aggregation in response to various agonists. Protein kinase C (PKC) activation is also known to be an important regulator of platelet activity. Using a newly developed selective inhibitor for 12-LOX and a pan-PKC inhibitor, we investigated the role of PKC in 12-LOX-mediated regulation of agonist signaling in the platelet. To determine the role of PKC within the 12-LOX pathway, a number of biochemical endpoints were measured, including platelet aggregation, calcium mobilization, and integrin activation. Inhibition of 12-LOX or PKC resulted in inhibition of dense granule secretion and attenuation of both aggregation and αIIbβ(3) activation. However, activation of PKC downstream of 12-LOX inhibition rescued agonist-induced aggregation and integrin activation. Furthermore, inhibition of 12-LOX had no effect on PKC-mediated aggregation, indicating that 12-LOX is upstream of PKC. These studies support an essential role for PKC downstream of 12-LOX activation in human platelets and suggest 12-LOX as a possible target for antiplatelet therapy.
血小板激活在止血和血栓形成的调节中起着重要作用。血小板的失控激活可能导致动脉血栓形成,这是心肌梗死和中风的主要原因。激活后,12-脂氧合酶(12-LOX)对花生四烯酸(AA)的代谢可能在调节血小板激活的程度和稳定性方面发挥重要作用,因为 12-LOX 的抑制可显著减弱血小板对各种激动剂的聚集。蛋白激酶 C(PKC)的激活也被认为是血小板活性的重要调节剂。使用新开发的 12-LOX 选择性抑制剂和泛 PKC 抑制剂,我们研究了 PKC 在 12-LOX 介导的激动剂信号调节血小板中的作用。为了确定 PKC 在 12-LOX 途径中的作用,测量了许多生化终点,包括血小板聚集、钙动员和整合素激活。12-LOX 或 PKC 的抑制导致致密颗粒分泌抑制,并减弱聚集和 αIIbβ(3)激活。然而,12-LOX 抑制后的 PKC 激活挽救了激动剂诱导的聚集和整合素激活。此外,12-LOX 的抑制对 PKC 介导的聚集没有影响,表明 12-LOX 在 PKC 之前。这些研究支持 12-LOX 激活后的 PKC 在人血小板中的重要作用,并表明 12-LOX 可能是抗血小板治疗的一个潜在靶点。